雷替曲塞联合顺铂治疗晚期食管癌的临床疗效观察  

Clinical Observation on the Efficacy of Raltitrexed Plus Cisplatin in Treatment of Patients with Advanced Esophageal Carcinoma

作　　者：陈守华[1] 姚卫东[1] 张娣娣[1] 季丛飞 CHEN Shouhua;YAO Weidong;ZHANG Didi(Nantong Oncology Hospital,Nantong,226300)

机构地区：[1]江苏省南通市肿瘤医院

出　　处：《实用癌症杂志》2019年第10期1662-1664,1687,共4页The Practical Journal of Cancer

摘　　要：目的观察雷替曲塞联合顺铂与紫杉醇脂质体联合顺铂治疗晚期食管癌的疗效差异。方法 60例晚期食管癌患者随机分为对照组和试验组,每组30例。对照组予紫杉醇脂质体联合顺铂化疗,试验组予雷替曲塞联合顺铂方案化疗。观察2组的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)、总生存时间(OS)和不良反应。结果试验组和对照组的ORR分别为33. 3%和26. 7%,DCR分别为63. 3%和56. 7%,差异均无统计学意义(P>0. 05)。试验组和对照组的PFS分别为(5. 13±0. 54)月和(4. 53±0. 55)月,OS分别为(9. 32±0. 74)月和(8. 93±0. 69)月,差异均无统计学意义(P> 0. 05)。试验组Ⅲ~Ⅳ级骨髓抑制、消化道反应、神经毒性发生率均低于对照组(P <0. 05);两组在转氨酶异常的发生率上差异无统计学意义(P> 0. 05)。结论雷替曲塞联合顺铂治疗不可手术切除的晚期食管癌,疗效不劣于紫杉醇脂质体联合顺铂,且不良反应发生率更低,耐受性好且给药更方便,值得在临床上进一步推广应用。Objective To investigate the therapeutic effect of raltitrexed plus cisplatin versus paclitaxel liposomses plus cisplatin for advanced esophageal carcinoma. Methods 60 patients with advanced esophageal carcinoma were randomly divided into the control group and the experimental group,30 cases per group. The experimental group was given chemotherapy with raltitrexed plus cisplatin,while the control group was given chemotherapy with paclitaxel liposomses plus cisplatin. The objective response rate、disease control rate、progress free survival、overall survival and adverse effect were observed. Results The objective response rate of experimental group was 33. 3%,and the disease control rate was 63. 3%,which had no statistical difference compare with 26. 7% and 56. 7% of control group( P > 0. 05). The PFS of the experimental group was( 5. 13 ± 0. 54),which had no statistical difference than that of the control group( 4. 53 ± 0. 55). The OS of the experimental group was( 9. 32 ± 0. 74),which had no statistical difference than that of the control group( 8. 93 ± 0. 69). The incidence rate of third and fourth bone marrow suppression,gastrointestinal reaction and neurotoxicity in the experimental group was lower than that of the control group. There was no statistically significant difference in the incidence of aminotransferase abnormalities between the 2 groups. Conclusion Raltitrexed plus cisplatin for advanced esophageal carcinoma is not inferior to paclitaxel liposomses plus cisplatin with lower adverse reactions incidence,it is worthy of clinical application and promotion.

关 键 词：食管癌 雷替曲塞 紫杉醇脂质体 顺铂 

分 类 号：R735.1[医药卫生—肿瘤]